If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.58    -0.025 (-1.52%)
Bid:
1.32
Ask:
1.93
Spread: 0.61 (46.212%)
Market Cap: £5.54m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Directorate Change

1 Jul 2014 07:00

RNS Number : 9952K
Proteome Sciences PLC
01 July 2014
 



 

 

 

 

 

PRESS RELEASE

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Appointment of Roger McDowell as Non-Executive Director

 

1st July, 2014 Proteome Sciences is pleased to announce the appointment of Roger Steven McDowell to the Board of the Company as a non-executive Director with immediate effect.

 

Roger McDowell has a highly successful career as a businessman and entrepreneur. He was Managing Director of Oliver Ashworth for eighteen years before its sale to St. Gobain. He is currently the Chairman or a non-executive director of seven listed companies, namely Avingtrans plc, Servelec Group plc, Renovo plc, Alkane Energy plc, Swallowfield plc, IS Solutions plc and Augean plc. He brings considerable commercial experience with him and is a keen exponent of growing shareholder value.

 

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Roger Steven McDowell, age 60 years, is or has been a director of the following companies during the five years preceding the date of this announcement:

 

Current directorships Past directorships

Corsair Techinvest Ltd One Advice Group plc

Fineguard Ltd Ultimate Finance Group plc

Augean plc

Disperse Ltd

Dovehoco 201 Ltd

Avingtrans plc

IS Solutions plc

Swallowfield plc

Alkane Energy plc

Renovo plc

Servelec Group plc

 

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies. 

 

At the AGM, held on 30 June 2014, it was announced that Steve Harris, the Chairman, was proposing to retire and he has now formally stepped down as a director.

 

The Board of Proteome Sciences would like to thank him for the considerable contribution and support that he has provided to the Company over the last 20 years, a period in which the Company's outstanding biomarker research has been converted into products, services and commercial revenue. We wish him a long and enjoyable retirement.

 

The CEO, Christopher Pearce, has been appointed Executive Chairman. Dr. Ian Pike remains the Chief Operating Officer.

 

 

- Ends -

 

 

 

 

 

 

For further information please contact:

Proteome Sciences plc

Christopher Pearce, Chief Executive Officer

Tel: +44 (0)1932 865065

Dr. Ian Pike, Chief Operating Officer

James Malthouse, Finance Director

Nominated Adviser

Cenkos

Stephen Keys/Callum Davidson

Tel: +44 (0)20 7397 8900

Public Relations

IKON Associates

Adrian Shaw

Tel: +44 (0)1483 271291

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAKBLFXZQFEBBD
Date   Source Headline
19th Nov 20145:08 pmRNSHolding(s) in Company
12th Nov 20147:00 amRNSTrading Update
16th Oct 20147:00 amRNSDirectorate Change
1st Oct 20143:54 pmRNSDirector/PDMR Shareholding
30th Sep 20147:01 amRNSBlocklisting Interim Review
30th Sep 20147:00 amRNSDirectorate Change
30th Sep 20147:00 amRNSHalf Yearly Report
26th Sep 20147:00 amRNSCK1d Update: Toxicity Results
25th Sep 201410:08 amRNSContract with Genting TauRx Diagnostic Centre
15th Sep 20147:00 amRNSScience and Technology Award
19th Aug 20147:00 amRNSAppointment of Joint Broker
8th Jul 20145:45 pmRNSDirector/PDMR Shareholding
8th Jul 20147:00 amRNSAlzheimer's blood test study
1st Jul 20147:00 amRNSDirectorate Change
30th Jun 20144:42 pmRNSResult of AGM
9th Jun 20144:18 pmRNSAnnual Financial Report
29th May 20147:00 amRNSPreliminary results
1st Apr 20147:00 amRNSBlocklisting Interim Review
27th Mar 20147:00 amRNSPancreatic Cancer Study in PLOS ONE
3rd Mar 20144:25 pmRNSDirectorate Change
28th Feb 20143:46 pmRNSHolding(s) in Company
24th Feb 20147:00 amRNSPlacing
7th Feb 20147:00 amRNSTrading Update
3rd Feb 20144:44 pmRNSHolding(s) in Company
27th Dec 20134:35 pmRNSPrice Monitoring Extension
4th Dec 20137:00 amRNSTrading Update
20th Nov 20137:00 amRNSPatient Stratification Biomarkers for Liver Cancer
6th Nov 20132:51 pmRNSHolding(s) in Company
1st Oct 201310:34 amRNSBlocklisting Interim Review
30th Sep 20137:00 amRNSHalf Yearly Report
18th Sep 20132:00 pmRNSKey Assay Development at HUPO
2nd Sep 201312:12 pmRNSHolding(s) in Company
6th Aug 201312:36 pmRNSIssue of Equity
18th Jul 20137:00 amRNSNew Data Shows CK1d Blocks Tau in AD Model
28th Jun 20131:00 pmRNSAGM Statement
28th Jun 20137:00 amRNSPatent Statement
26th Jun 20139:27 amRNSHolding(s) in Company
12th Jun 20137:00 amRNSMajor technology contract
5th Jun 20134:08 pmRNSAnnual Financial Report
30th May 20137:01 amRNSPreliminary Results
19th Apr 20137:00 amRNSTrading Update
2nd Apr 20137:00 amRNSBlock admission return
18th Mar 20137:00 amRNSDevelopments in Alzheimer's Disease
22nd Jan 20137:00 amRNSTrading Statement
31st Dec 20127:00 amRNSCK1D Update
3rd Dec 201211:06 amRNSHolding(s) in Company
28th Sep 20127:00 amRNSHalf Yearly Report
18th Sep 20124:04 pmRNSBlock Admission Return
18th Sep 20124:01 pmRNSBlock Admission Return
18th Sep 20127:00 amRNSFurther re. University of Geneva Study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.